公开(公告)号：US10662482B2

公开(公告)日：2020-05-26

申请号：US15177055

申请日：2016-06-08

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  INSTITUT GUSTAVE-ROUSSY ,  ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS ,  CENTRE HENRI BECQUEREL ,  UNIVERSITE PARIS DESCARTES ,  UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) ,  UNIVERSITE PARIS-SUD

发明人： Franck Viguie ,  Olivier Bernard ,  Michaela Fontenay ,  Christian Bastard ,  Francois Delhommeau ,  William Vainchenker

IPC分类号： C12Q1/6886 ,  G01N33/574 ,  A61K31/7068

摘要： The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.

公开(公告)号：US11203788B2

公开(公告)日：2021-12-21

申请号：US16843507

申请日：2020-04-08

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  INSTITUT GUSTAVE-ROUSSY ,  Assistance Publique—Hopitaux de Paris ,  Centre Henri Becquerel ,  Universite Paris Descartes ,  Universite Pierre et Marie Curie ,  Universite Paris—SUD

发明人： Franck Viguie ,  Olivier Bernard ,  Michaela Fontenay ,  Christian Bastard ,  Francois Delhommeau ,  William Vainchenker

IPC分类号： C12Q1/6886 ,  G01N33/574 ,  A61K31/7068

摘要： The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.

公开(公告)号：US20160319362A1

公开(公告)日：2016-11-03

申请号：US14917087

申请日：2014-09-11

申请人： UNIVERSITE DE ROUEN ,  CENTRE HENRI BECQUEREL ,  INSTITUT NATIONAL DE LA SANTÉ ET LA RECHERCHE MÉDICALE

发明人： Philippe RUMINY ,  Vinciane MARCHAND ,  Fabrice JARDIN

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158

摘要： A method for diagnosing a cancer in a subject, notably with the aim of finding fusion transcripts, includes an RT-MLPA step carried out on a biological sample obtained from the subject using the probes SEQ ID NO: 1 to 25, 30, 31 and 113 to 120, and/or with at least the probes SEQ ID NO: 374 to 405, and/or with at least the probes SEQ ID NO: 524 to 559, each of the probes being fused, at one end at least, with a priming sequence.

摘要翻译： 用于诊断受试者中癌症的方法，特别是为了寻找融合转录物，包括使用探针SEQ ID NO：1至25,30,31和从探针获得的生物学样品进行的RT-MLPA步骤 113至120和/或至少具有探针SEQ ID NO：374至405和/或至少探针SEQ ID NO：524至559的探针，每个探针在一端至少与 启动序列。

公开(公告)号：US20220165355A1

公开(公告)日：2022-05-26

申请号：US17598775

申请日：2020-03-27

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE(INSERM) ,  UNIVERSITÉ DE ROUEN-NORMANDIE ,  CENTRE HENRI BECQUEREL

发明人： Philippe RUMINY ,  Vinciane MARCHAND ,  Victor BOBÉE ,  Fabrice JARDIN

IPC分类号： G16B25/10 ,  C12N15/10 ,  C12Q1/6886 ,  G16B40/20

摘要： An accurate gene expression based classifier, and the associated assay, which can participate to the establishment a lymphoma diagnosis and to the evaluation of individual prognosis markers are provided. Through its use, one may distinguish subtypes of lymphomas such as ABC DLBCL, GCB DLBCL, PMBL, FL, MCL, SLL and MZL from one another.

公开(公告)号：US20170016074A1

公开(公告)日：2017-01-19

申请号：US15124580

申请日：2015-03-10

申请人： INSERM (Institute National de la Sante et de la Research Medicale) ,  Universite de Rouen ,  Centre Henri Becquerel

发明人： Fabrice Jardin ,  Philippe Ruminy ,  Sylvain Mareschal ,  Vinciane Marchand ,  Cristina Bagacean

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/16

摘要： The present invention relates to a method for classifying a diffuse large B-cell lymphoma (DLBCL) of a subject into a GCB-DLBCL or into a ABC-DLBCL comprising the step of determining the expression level of 10 genes in a tumor tissue sample obtained from the subject by performing a Reverse Transcriptase Multiplex Ligation dependent Probe Amplification (RT-MLPA) assay wherein the 10 genes are NEK6, IRF4, IGHM, LMO2, FOXP1, TNFRSF9, BCL6, TNFRSF13B, CCND2 and MYBL1.

摘要翻译： 本发明涉及将受试者的弥漫性大B细胞淋巴瘤（DLBCL）分类为GCB-DLBCL或ABC-DLBCL的方法，所述方法包括确定获得的肿瘤组织样品中10个基因的表达水平的步骤 通过进行逆转录酶多重连接依赖性探针扩增（RT-MLPA）测定，其中10个基因是NEK6，IRF4，IGHM，LMO2，FOXP1，TNFRSF9，BCL6，TNFRSF13B，CCND2和MYBL1。

公开(公告)号：US20160319370A1

公开(公告)日：2016-11-03

申请号：US15177055

申请日：2016-06-08

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  INSTITUT GUSTAVE-ROUSSY ,  ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS ,  CENTRE HENRI BECQUEREL ,  UNIVERSITE PARIS DESCARTES ,  UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) ,  UNIVERSITE PARIS-SUD

发明人： Franck Viguie ,  Olivier Bernard ,  Michaela Fontenay ,  Christian Bastard ,  Francois Delhommeau ,  William Vainchenker

IPC分类号： C12Q1/68 ,  A61K31/7068

CPC分类号： C12Q1/6886 ,  A61K31/7068 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57426

摘要： The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.

摘要翻译： 本发明涉及一种用于诊断受试者中骨髓瘤或淋巴样肿瘤的体外方法，其包括通过以下步骤：分析来自所述受试者的生物样品：（i）检测十一易位蛋白家族中的突变的存在 编码具有序列SEQ ID NO：2的多肽的成员2基因（TET2）和/或（ii）分析TET2基因的表达; 其中检测这种TET2突变，不存在TET2的表达或截短的TET2的表达指示受试者发展或倾向于发展骨髓瘤或淋巴样肿瘤。

公开(公告)号：US20220290242A1

公开(公告)日：2022-09-15

申请号：US17291407

申请日：2019-11-05

申请人： CENTRE HENRI BECQUEREL ,  UNIVERSITE DE ROUEN-NORMANDIE ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCH MÉDICALE)

发明人： Philippe RUMINY ,  Vinciane MARCHAND ,  Ahmad ABDEL SATER ,  Pierre-Julien VIAILLY ,  Marie Delphine LANIC ,  Fabrice JARDIN ,  Marick LAE ,  Mathieu VIENNOT

IPC分类号： C12Q1/6886

摘要： The invention concerns a method for diagnosing a cancer in a subject, comprising a step of RT-MLPA on a biological sample obtained from the subject, in which the RT-MLPA step is carried out using at least one pair of probes comprising at least one probe chosen among the probes with SEQ ID NO: 1 to 13, and/or the probes with SEQ ID NO: 96 to 99, and/or the probes with SEQ ID NO: 866 to 938, and/or the probes with SEQ ID NO: 940 to 1104, and/or SEQ ID NO: 211 to 1312, and/or the probes with SEQ ID NO: 96 to 99, and/or the probes with SEQ ID NO: 1105 to 1107 and/or the probe with SEQ ID NO: 939 and/or the probes with SEQ ID NO: 1108 to 1123, each of the probes being fused, at at least one end, with a priming sequence, and at least one of the probes of the pair comprising a molecular barcode sequence.

公开(公告)号：US20200255912A1

公开(公告)日：2020-08-13

申请号：US16843507

申请日：2020-04-08

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  INSTITUT GUSTAVE-ROUSSY ,  Assistance Publique - Hopitaux de Paris ,  Centre Henri Becquerel ,  Universite Paris Descartes ,  Universite Pierre et Marie Curie ,  Universite Paris - SUD

发明人： Franck VIGUIE ,  Olivier BERNARD ,  Michaela FONTENAY ,  Christian BASTARD ,  Francois DELHOMMEAU ,  William VAINCHENKER

IPC分类号： C12Q1/6886 ,  G01N33/574 ,  A61K31/7068

摘要： The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.

公开(公告)号：US10519508B2

公开(公告)日：2019-12-31

申请号：US15124580

申请日：2015-03-10

申请人： INSERM (Institute National de la Sante et de la Recherche Medicale) ,  Universite de Rouen ,  Centre Henri Becquerel

发明人： Fabrice Jardin ,  Philippe Ruminy ,  Sylvain Mareschal ,  Vinciane Marchand ,  Cristina Bagacean

IPC分类号： C12Q1/6886

摘要： The present invention relates to a method for classifying a diffuse large B-cell lymphoma (DLBCL) of a subject into a GCB-DLBCL or into a ABC-DLBCL comprising the step of determining the expression level of 10 genes in a tumor tissue sample obtained from the subject by performing a Reverse Transcriptase Multiplex Ligation dependent Probe Amplification (RT-MLPA) assay wherein the 10 genes are NEK6, IRF4, IGHM, LMO2, FOXP1, TNFRSF9, BCL6, TNFRSF13B, CCND2 and MYBL1.